2018年6月1日星期五

In vivo Charakterisierung Amyloid-β-Oligomer eliminierender D-enantiomerer Peptide zur Therapie der Alzheimer'schen Demenz

In vivo Charakterisierung Amyloid-β-Oligomer eliminierender D-enantiomerer Peptide zur Therapie der Alzheimer'schen Demenz

S Schemmert - 2018 - docserv.uni-duesseldorf.de
Beschreibungen: Die Alzheimer'sche Demenz (AD) ist eine unheilbare, neurodegenerative
Erkrankung, pathologisch charakterisiert durch zerebrale Amyloid-β (Aβ)-Ablagerungen und
neurofibrilläre Bündel, einhergehend mit einem progressivem Verlust der …


For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to >99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.

Eva He
eva@pepmic.com
Pepmic Co., Ltd
www.pepmic.com


没有评论:

发表评论